Psen2 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Psen2 Mutations In Alzheimer'S Disease represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
Presenilin 2 (PSEN2) is a less common cause of autosomal dominant familial Alzheimer's disease, with approximately 40 pathogenic mutations identified. PSEN2 encodes the second catalytic subunit of γ-secretase, with mutations causing a later-onset and more variable form of familial AD compared to PSEN1.
- Gene: PSEN2 (Presenilin 2)
- Chromosome: 1q42.13
- Mutations: ~40 pathogenic variants identified
- Inheritance: Autosomal dominant with reduced penetrance
- Prevalence: ~5-10% of familial AD cases
Presenilin 2 is a homolog of presenilin 1:
- Proteolytic cleavage: Catalytic subunit of γ-secretase
- Aβ generation: Produces Aβ40 (~90%) and Aβ42 (~10%)
- Notch signaling: Essential for Notch receptor cleavage
- Protein maturation: Assists in γ-secretase complex assembly
- Aβ42/Aβ40 ratio: Most PSEN2 mutations increase the ratio
- Reduced penetrance: Not all carriers develop AD
- Later onset: Average onset 5-10 years later than PSEN1
- γ-secretase dysfunction: Altered cleavage specificity
- Aβ42 elevation: Increases amyloid nucleation
- Calcium dysregulation: Mitochondrial calcium homeostasis disrupted
- Protein misfolding: ER stress response activated
- Variable penetrance: Environmental and genetic modifiers
| Mutation |
Age of Onset |
Penetrance |
Aβ Effect |
| N141I |
~55-70 years |
~95% |
Aβ42 ↑ |
| M239V |
~60-75 years |
~80% |
Aβ42 ↑ |
| T122P |
~60-70 years |
Variable |
Aβ42 ↑ |
| S130L |
~65-75 years |
Reduced |
Aβ42 ↑ |
| A85V |
Variable |
Low |
Mild effect |
The original PSEN2 mutations were identified in the Volga-German families:
- N141I (Asn141Ile): Most common and best-characterized
- M239V (Met239Val): Found in German families
- Rare variants: Various other pathogenic mutations
- Range: 50-80 years (most commonly 55-70)
- Later than PSEN1: ~5-10 years later on average
- Variable: Even within families
- Memory impairment: Progressive episodic memory loss
- Progression: Variable rate, often slower than PSEN1
- Behavioral symptoms: Less prominent than PSEN1
- Parkinsonism: Can present in some families
- Cerebral amyloid angiopathy: More common than PSEN1
- Amyloid plaques: Predominantly Aβ42 deposition
- Neurofibrillary tangles: Tau pathology present
- Cerebral amyloid angiopathy: More frequent than PSEN1
- Vascular changes: Associated with CAA
- Early-to-mid-onset AD (< 70 years)
- Autosomal dominant family history
- Variable penetrance within family
- Cerebral amyloid angiopathy with dementia
- Pathogenic mutations: Confirm diagnosis, inform family
- Reduced penetrance: May not develop symptoms
- Variants of uncertain significance: Require functional studies
| Feature |
PSEN1 |
PSEN2 |
| Age of onset |
30-60 years |
50-75 years |
| Penetrance |
~100% |
70-95% |
| Mutation count |
>200 |
~40 |
| Phenotype |
More severe |
More variable |
| CAA frequency |
Lower |
Higher |
- γ-secretase modulators: May benefit PSEN2 carriers
- Aβ42 antibodies: Potential therapeutic benefit
- Anti-aggregation drugs: Target toxic Aβ species
- PSEN2 carriers eligible for prevention trials
- DIAN-TU: Includes PSEN2 mutation carriers
- API: Alzheimer's Prevention Initiative
Psen2 Mutations In Alzheimer'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Psen2 Mutations In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lleo A, et al. (2018). Clinical, pathological, and genetic spectrum of presenilin 2 mutations. Neurology.
- Ryman DC, et al. (2015). Symptomatic and preventive therapy in dominantly inherited Alzheimer's disease. Neurology.
- Jayadev S, et al. (2010). Presenilin mutations and Alzheimer's disease. Cold Spring Harbor Perspectives in Medicine.
- Alzheimer's Disease Genetics Consortium. (2019). PSEN2 variant interpretation. Genetics in Medicine.